Stay updated on Lenalidomide and Daratumumab in High-Risk Smoldering Myeloma Clinical Trial
Sign up to get notified when there's something new on the Lenalidomide and Daratumumab in High-Risk Smoldering Myeloma Clinical Trial page.

Latest updates to the Lenalidomide and Daratumumab in High-Risk Smoldering Myeloma Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedA new revision tag v3.6.5 was added to the record history, replacing the previous v3.6.4, indicating an updated version of the study record. This change updates the record's metadata rather than trial data or outcomes.SummaryDifference0.1%

- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedThe study record's revision history gains a new entry for v3.6.4 and removes the previous v3.6.3 entry, indicating an update to the page's revision history.SummaryDifference0.1%

- Check48 days agoChange DetectedA new revision entry, v3.6.3, was added to the record history. The previous revision, v3.6.2, was removed from the list.SummaryDifference0.1%

- Check55 days agoChange DetectedA new revision entry, v3.6.2, was added to the study history and the earlier revision v3.6.0 was removed, updating the historical log displayed on the page.SummaryDifference0.1%

- Check62 days agoChange DetectedThe study history page now includes new sections for Contacts/Locations and Study Status, expanding access to site contacts and the current trial status. An added numeric item likely represents a version or count marker associated with the update.SummaryDifference0.4%

- Check69 days agoChange DetectedAdds quick access to eligibility (Check who can join) and contact information (Find Contact Information) on the study record page. Updates the revision badge to v3.6.0 and removes the previous v3.5.5 entry.SummaryDifference0.4%

Stay in the know with updates to Lenalidomide and Daratumumab in High-Risk Smoldering Myeloma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Lenalidomide and Daratumumab in High-Risk Smoldering Myeloma Clinical Trial page.